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Description of the technology
Tumor rejection antigens allow tumors sufficiently
distinct from normal tissue to activate the immune sys-
tem and induce an efficient anti-tumor response. Tumor
mutated specific antigens (TMSA, neoantigens) without
central tolerance are major tumor rejection antigens.
The recent developments of innovative deep sequencing
technologies (at an affordable cost) along with advances
in bioinformatics have enabled systemic analysis of the
mutation load of the tumor as well as identification of
the potentially immunogenic neoantigens. T cell reactiv-
ity against these predicted neoantigens can then be ana-
lyzed [1, 2]. This novel approach allows the discovery of
the mutated genes in individual tumors and assessment
of the immunogenicity of these neoepitopes. It consists
of several key steps as illustrated in Fig. 1, including a)
sample collection and storage, b) whole exome sequen-
cing to identify the mutations by using different compu-
tational and mutation calling tools, c) RNA-seq analysis
to focus specifically on the expressed mutations, d) iden-
tification of neoepitopes in silico with computational
algorithms for MHC class I and class II binding as well
as e) use of tandem minigene libraries for class II epi-
tope screening and f) neoantigen specific T cell assays to
differentiate trueimmunogenic neoepitopes from puta-
tive ones. Tumor and non-transformed cells (usually
PBMCs) from the same patients can be sequenced to de-
termine the mutation load and the full range of genomic
alterations within a tumor, such as nucleotide substitu-
tions, structural rearrangements and copy number
alterations. The data to date indicate that the vast major-
ity of mutated antigens are not shared between patients,
and are considered patient-specific [1]. The genetic land-
scape and the full spectrum of genomic alterations in
each individual tumor provide potential guidance for
personalized cancer immunotherapy and precision
oncology.
Type of data obtained/readout
Deep sequencing to assess the mutations present within
the protein-encoding regions of the genome (the exome)
of an individual tumor will generate a unique set of data
for each tumor. Whole exome sequencing data from the
tumor sample and non-transformed cells will be used to
detect nonsynonymous somatic mutations with the use
of mutation calling tools. RNA seq analysis will be used
to identify expressed mutations in order to predict po-
tential neoantigens. Epitope prediction algorithms based
on published or submitted MHC Class I and II binding
data will provide estimates of binding affinity to identify
putative T cell neoepitopes. Data resulting from func-
tional assays, including combinatorial encoding of MHC
multimer screening flow cytometry assays, or functional
read outs such as cytokine production, will provide an in-
dication of T cell reactivity to validate the tumor-specific
immunogenic neoepitopes. The analyses of mutations in
MHC class I and II genes as well as key molecules affect-
ing antigen processing and presentation are vital to pro-
vide a better assessment of their potential impact on
cytolytic T cell responses. The genetic landscape, the pool
of neoepitopes and functional tumor rejection measures
of neoantigen-specific T cells (tumor recognition) could
be used to further assess their relevance to clinical
outcome, design therapeutic tumor-specific neoantigen
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(TSNA) vaccination, apply adoptive neoantigen T cell
transfer therapy and to guide more effective immuno-
oncology combination immunotherapy.
Limitations of the approach
One of the major limitations of this approach is in the
early stage computational tools that are used both to
identify tumor-specific mutations and to guide epitope
prediction. Multiple computational tools, such as EBcall,
JointSNVMix, MuTect, SomtaticSniper, Strelka and
VarScan 2, are used to compare tumor samples to nor-
mal tissue at each variant locus to increase the accuracy
of somatic single nucleotide variant (sSNV) calling [3–7].
Because these tools use distinct variant calling algorithms,
there may be variability in the somatic mutations identi-
fied. Thus, more validation studies are necessary to im-
prove the calling tools and standardize their use.
Computer algorithm-guided epitope prediction and the
tandem minigene library approach are used to identify
MHC Class I or II binding neoepitopes recognized by
neoantigen specific CD8+ and CD4+ T cells, respectively
[8–10]. The accuracy of the prediction algorithms mostly
depends upon the binding scores to the MHC complex,
with the Class II prediction tools being much less well-
developed than Class I. Tumors, especially those with mu-
tant and viral antigens, could be sufficiently “foreign” to
be recognized by the immune system. However, current
data has illustrated that autologous T cells did not
recognize the vast majority of neoepitopes. Although the
epitope prediction tools have been shown to have a high
degree of overlap [11–14], it is important to improve the
ability of these tools to differentiate putative neoepitopes
from real immunogenic neoepitopes [15]. This lack of im-
munogenicity could also be due to the tumor’s inability to
activate the immune system because of additional resist-
ance mechanisms, especially tumor microenvironment
factors, rather than the absence of tumor antigens. Be-
cause the activation and cytotoxic signals in individual tu-
mors may reflect the overall status of a neoantigen-specific
tumor response, it will be critical to further evaluate these
functional signatures and to incorporate them into future
optimized pipelines.
Another potential limitation of this technology is that
representative, high-quality tissue samples are needed in
order to produce reliable results. Tumor tissue from
formalin-fixed, paraffin-embedded (FFPE) samples may
be used for whole exome sequencing. However, proper
collection and storage of the tumor tissue is essential to
ensure high quality DNA for deep sequencing. Because
of the heterogeneity of the tumor, it is also essential to
collect representative tissue to avoid any bias. In
addition, mutational profiles may change due to dis-
ease progression or ongoing treatment. Therefore,
assessing the tumor sample closest to the intervention
is best to eliminate the potential variation and in-
crease accuracy. Moreover, although PBMCs are com-
monly used as non-transformed cells, the signal from
even low frequency circulating tumor cells from
whole blood needs to be further validated for poten-
tial contribution to data noise.
Fig. 1 Current potential pipelines of whole exome sequencing for neoantigen discovery and precision oncology. After sample collection, whole
exome sequencing can be performed on both tumor and non-transformed cells from the same patient. Once tumor specific mutations are identified,
RNA-seq can be utilized to determine the level of expression of the mutations. Computational tools and/or a tandem minigene library are used to
identify the neoepitopes, T cell assays to narrow down the true immunogenic neoepitope for efficient assessment and precise prediction and neoantigen
vaccination targets. Neoantigen discovery also provides guidance for adaptive neoantigen T cell transfer therapy and combination immunotherapy
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Types of samples needed and special issues
pertaining to samples
Tissue from the tumor sample and non-transformed
cells are needed for whole exome sequencing. However,
as mentioned above, proper collection and storage of
representative tissue is essential to ensure high-quality
samples for deep sequencing. For downstream assess-
ment of T cell reactivity in functional assays, TILs and
PBMCs are needed and must be viably preserved as a
single-cell suspension.
Level of evidence
This is a novel technology that is still currently under
development. Two pilot preclinical studies in mouse
models first demonstrated that whole exome sequencing
is efficient to identify neoantigen-specific CD8+ T cells
with tumor elimination [16, 17]. Several human clinical
studies highlighted the feasibility and importance of un-
derstanding the immunogenicity of neoantigens and
their potential clinical application in patients treated
with tumor-infiltrating lymphocyte cells [8–10]. The
level of mutational load (or the mutational landscape) as
a potential biomarker was associated with clinical out-
come to immune checkpoint blockade cancer immuno-
therapy in patients with advanced melanoma, non-small
cell lung cancer (NSCLC) and colorectal cancer [18–21].
Patients with highly mutagenized tumors and activated
cytolytic markers are most likely to respond to check-
point blockade treatment [22]. In this study, epitope pre-
diction did not improve clinical outcome prediction
value [23]. However, some patients with a high muta-
tional load do not experience clinical responses, while
some patients with a low mutation profile experience
substantial clinical responses [18, 19]. Assessment of
clinically relevant immunogenic mutation loads along
with active cytolytic signatures before therapy is pivotal
to improve the accuracy of outcome prediction. As the
study was performed in patients with mismatched repair
deficiency tumors [20], more prospective studies must
be performed to determine whether the mutation load
can guide novel therapeutic approaches to selectively en-
hance T cell response to neoantigens in future mono- or
combination therapies.
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